As the practices selected were active in research, blood pressure control in these practices may be better than in the UK as a whole. Our analysis was based on the latest blood pressure recorded in the general practice records. This will have reflected several recordings of blood pressure in some cases and a single reading in other instances. This may have resulted in an overestimation of "true" blood pressure in this stroke population compared with measurements in the controlled setting of a study, but these are the readings on which management will be decided.

Current national and international guidelines may give appropriate advice for the management of blood pressure of younger patients who have had a recent cerebrovascular event. Unfortunately, these guidelines may act as an impediment to further research. We would urge that further evidence should be collected on the efficacy and adverse effects of intensive blood pressure lowering in representative populations before we implement this guidance in primary care.

Contributors: JM conceived and designed the study and analysed the data. RMCM assisted in the design and analysis and supervised the data collection from practices. RH was responsible for data collection. All authors contributed to the drafting of the paper. JM is the guarantor.

Funding: The research was supported by the Stroke Association. RMCM was funded by a Department of Health national primary care researcher development award.

Competing interests: None declared.

Ethical approval: South Birmingham Local Research Ethics Committee approved the study.

- 1 Intercollegiate Stroke Working Party. *National clinical guidelines for stroke*. 2nd ed. London: Royal College of Physicians of London, 2004.
- 2 Williams B, Poulter NR, Brown MJ, Davis M, McNnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. *J Hum Hypertens* 2004;18:139-85.
- 3 Chalmers J, Todd A, Chapman N, Beilin L, Davis S, Donnan G, et al. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. *J Hypertens* 2003;21:651-63.
- 4 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003;42:1206-52.
- 5 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with a previous stroke or transient ischaemic attack. *Lancet* 2001;358:1033-41.
- 6 Wennberg R, Zimmermann C. The PROGRESS trial three years later: time for a balanced report of effectiveness. *BMJ* 2004;329:968-71.
- 7 Mant J, McManus RJ, Hare R, Mayer P. Identification of stroke in the community: a comparison of three methods. *Br J Gen Pract* 2003;53:520-4.
- 8 Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekblom T, Fagard R, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. *Lancet* 1999;353:793-6.
- 9 Lovett JK, Dennis MS, Sandercock PAG, Bamford J, Warlow CP, Rothwell PM. Very early risk of stroke after a first transient ischaemic attack. *Stroke* 2003;34:e138-42.
- 10 National Statistics. *Mortality statistics: cause*. London: Stationery Office, 2000. (Series DH2 No 26.)
- 11 West Midlands Public Health Observatory. *Key health data for the West Midlands, 2001*. Birmingham: Department of Public Health and Epidemiology, 2002. (Report No 31.)
- 12 Sproston K, Primatesta P, eds. *Health survey for England 2003. Volume 1: cardiovascular disease*. London: Stationery Office, 2004.
- 13 Office for National Statistics. *Key health statistics from general practice 1998*. London: Stationery Office, 2000.
- 14 Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire UK from 1981 to 2004 (Oxford vascular study). *Lancet* 2004;363:1925-33.

(Accepted 10 January 2006)

doi 10.1136/bmj.38758.600116.AE

Intramuscular gluteal injections in the increasingly obese population: retrospective study

Andrew Charles Nisbet

Abstract

Aims To examine depth of subcutaneous fat at gluteal intramuscular injection sites.

Design Retrospective study.

Setting General hospital.

Participants 100 consecutive adults who had computed tomography of the pelvis.

Main outcome measures Minimum distance between the surface of the skin and the nearest edge of muscle at intramuscular injection sites.

Results 12 patients had a ventrogluteal site depth of more than 35 mm, the maximum depth of a green needle, and 26 had a ventrogluteal depth of more than 25 mm, the maximum depth of a blue needle. 43 patients had a dorsogluteal site depth of more than 35 mm, and 72 had a dorsogluteal depth of more than 25 mm. The intramuscular site was likely to be deeper in women.

Conclusion Standard green and blue needles do not reach the gluteal muscles in a considerable number of patients.

Introduction

Studies of intramuscular injections have shown differences in peak plasma concentrations of narcotics

and in perceived pain relief, depending on gluteal or deltoid injection site.¹ Response levels to vaccination vary according to intramuscular injection site.² Different responses depending on site have also been noticed for injections of antibiotics,³ insulin, and lignocaine.⁴

Possible reasons for this variation in efficacy include different ratios of adipose to lean muscle tissue, greater blood flow in deltoid than gluteal muscle,⁵ and positional external compression of the gluteus. In a population that is increasingly overweight, these factors could become more exaggerated, leading overall to less effective intramuscular gluteal injections. Additionally, if the depth of fat is so great that the needle cannot reach the muscular layer in many patients, the average absorption of the drug in the population will be lower.

Method

Scans from 100 consecutive adults (39 men, 61 women; mean 47.8 (SD 11.3) years; range 22-65 years) who had computed tomography scans of the pelvis

Jersey General Hospital, St Helier, Jersey JE2 3QS
Andrew Charles Nisbet
senior house officer in anaesthetics

Correspondence to:
Le Grupe, Les Grupieaux, St Peter, Jersey JE3 7ED
kaltarn@yahoo.co.uk

BMJ 2006;332:637-8

This article was posted on bmj.com on 8 March 2006:
<http://bmj.com/cgi/doi/10.1136/bmj.38706.742731.47>

were included in the study. I used automated computed tomography callipers to determine the minimum distance between the surface of the skin and the nearest edge of muscle at the ventrogluteal and dorsogluteal injection sites. (To determine the ventrogluteal site, place the ball of the opposing hand on the greater trochanter and index finger on the anterior superior iliac crest; form a V with the middle finger; the injection site is within the V.⁶ The dorsogluteal site is the upper outer quadrant of the buttock.⁷) I also correlated the depth at both sites with age and sex of the patients.

Results

The depth of adipose tissue at the ventrogluteal site ranged from 2.5 mm to 62.6 mm (mean 19.0 (12.8) mm). In 12 patients the depth was more than 35 mm, the extent of a green needle, and in 26 the depth was more than 25 mm, the extent of a blue needle. The depth at the dorsogluteal site ranged from 7.5 mm to 59.8 mm (mean 32.0 (10.5) mm). In 43 patients the depth was more than 35 mm, and in 72 the depth was more than 25 mm.

Age was not correlated with dorsogluteal depth, but increasing age was related to increasing ventrogluteal depth ($P < 0.01$, Pearson's correlation coefficient).

Site depth was markedly different in men and women. In the ventrogluteal site, 10 of 61 (16%) women had a depth of > 35 mm and 22 (36%) a depth of > 25 mm, whereas 2 of 39 (5%) men had a depth of > 35 mm and 4 (10%) of > 25 mm. In the dorsogluteal site, 35 (57%) women had a depth of > 35 mm and 55 (90%) of > 25 mm, whereas 8 (21%) men had a depth of > 35 mm and 17 (44%) of > 25 mm. All differences between men and women were significant ($P < 0.01$, χ^2 test, except $P < 0.05$ for ventrogluteal depth > 35 mm).

Discussion

Due to the depth of fat, intramuscular injections with large (green) needles into the anterior gluteal site in this sample would be subcutaneous in 12% of patients (16% of women and 5% of men), and for injections with smaller (blue) needles in 26% (36% of women and 10% of men). In the posterior gluteal site, large needles will fail to reach muscle in 43% (57% of women and

What is already known on this topic

The gluteal site can be less effective for intramuscular injections than other sites, such as deltoid

What this study adds

The gluteal muscles are beyond the reach of standard green and blue needles in a significant minority of patients

21% of men), and small needles will fail in 72% (90% of women and 44% of men).

The number of patients used in this study was small, and they were recruited only from a local population and did not include the extremes of age. Although the depth of their gluteal intramuscular injection sites may vary from the national average, this study shows that in a significant minority of patients the standard green or blue needles, which are the normal method of delivery, will fail to reach muscle. In highly obese populations, the depth could be expected to be even greater than that shown here.

As previous studies have shown low efficacy of gluteal intramuscular injections, this route should be avoided for most drugs. If alternative routes are not possible, using longer needles should be considered.

Contributors: ACN is the sole contributor and is guarantor.

Funding: None.

Competing interests: None declared.

Ethical approval: Not required.

- 1 Grabinski P, Kaiko RF, Rogers AG, Houde RW. Plasma levels and analgesia following deltoid and gluteal injections of methadone and morphine. *J Clin Pharmacol* 1983;23:48-55.
- 2 Lindsay KL, Herbert DA, Gitnick GL. Hepatitis B vaccine: low postvaccination immunity in hospital personnel given gluteal injections. *Hepatology* 1985;5:1088-90.
- 3 Vukonovich RA, Brannick LJ, Sugerman AA, Neiss ES. Sex differences in the intramuscular absorption and bioavailability of cephadrine. *Clin Pharmacol Ther* 1975;18:215-20.
- 4 Cohen LS, Rosenthal JE, Horner DW Jr, Atkins JM, Matthews OA, Sarnoff SJ. Plasma levels of lidocaine after intramuscular administration. *Am J Cardiol* 1972;29:520-3.
- 5 Evans EF, Proctor JD, Fratin MJ, Velandia J, Wasserman AJ. Blood flow in muscle groups and drug absorption. *Clin Pharmacol Ther* 1974;17:44-7.
- 6 Grabinski PY. IM injections—deltoid or gluteal site? *PRN Forum* 1983;2:2-3.
- 7 Greenway, K. Using the ventrogluteal site for intramuscular injections. *Nursing Standard* 2004;18(25):39-42.

(Accepted 21 November 2005)

doi 10.1136/bmj.38706.742731.47

An instrumental history of medicine

While holding a Langenbeck retractor for my consultant for the umpteenth time, I began to wonder who it was named after and what this figure contributed to surgery. My curiosity piqued, I set off to the Wellcome Institute one afternoon and uncovered the fascinating history of the Langenbeck retractor.

Conrad Johann Martin Langenbeck (1776-1851) was professor of surgery and anatomy in Göttingen. He was an infamous, accomplished surgeon, known for his speed. It is said that a colleague, in turning away to take a pinch of snuff, missed Langenbeck perform a shoulder amputation.

His most famous operation was the first vaginal hysterectomy in 1813. It was carried out on a 50 year old multiparous woman, possibly with cancer of the cervix. He performed this feat without

anaesthesia or an assistant. At one point, he was left clutching the bleeding area in his left hand, holding one end of a ligature with his teeth, and tying the other end with his right hand.

Langenbeck claimed a careful dissection so as not to open the peritoneal cavity. There was considerable haemorrhage, but, amazingly, the patient survived, revived by a splash of water to the face. After the operation, however, the specimen was lost, and Langenbeck's achievement was doubted by the medical fraternity until, 26 years later, the patient died and a postmortem examination confirmed his statement.

Rajvinder Khasriya senior house officer, obstetrics and gynaecology, St Thomas' Hospital, London (rajvinderkhasriya@hotmail.com)